Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

Figure 1

MM-121 significantly enhances paclitaxel-mediated anti-proliferative/anti-survival effects on breast cancer cell lines with expression of both erbB2 and erbB3. (A) SKBR3.neo1, SKBR3.B3.1, or SKBR3.B3.2 cells were plated onto 96-well plates and incubated at 37°C with 5% CO2. After 24 h, the culture medium was replaced with 0.1 ml fresh medium containing 0.5% FBS or the same medium containing the indicated concentrations of paclitaxel in the absence (paclitaxel) or presence (MM-121 + pac) of MM-121 (10 μg/ml) for another 72 h. The percentages of surviving cells from each cell line relative to controls, defined as 100% survival, were determined by reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS). Bars represent SD. Data are representative of three independent experiments. (B) The same cells were untreated or treated with MM-121 (10 μg/ml) for 24 or 48 h. Cells were collected and subjected to western blot analyses of phosphorylated (P)-erbB2, erbB2, P-erbB3, erbB3, P-Akt, Akt, P-mitogen-activated protein kinase (P-MAPK), MAPK, or β-actin.

Back to article page